<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Insmed Inc — News on 6ix</title>
<link>https://6ix.com/company/insmed-inc</link>
<description>Latest news and press releases for Insmed Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/insmed-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835841578dffbe2df0fcf5c.webp</url>
<title>Insmed Inc</title>
<link>https://6ix.com/company/insmed-inc</link>
</image>
<item>
<title>Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-to-host-first-quarter-2026-financial-results-conference-call-on-thursday-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-to-host-first-quarter-2026-financial-results-conference-call-on-thursday-may-7-2026</guid>
<pubDate>Thu, 23 Apr 2026 11:00:00 GMT</pubDate>
<description>Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its first-quarter 2026 financial results on Thursday, May 7, 2026.</description>
</item>
<item>
<title>Insmed Provides Clinical Update on Phase 2b CEDAR Study</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-provides-clinical-update-on-phase-2b-cedar-study</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-provides-clinical-update-on-phase-2b-cedar-study</guid>
<pubDate>Tue, 07 Apr 2026 20:01:00 GMT</pubDate>
<description>Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the Phase 2b CEDAR study, which evaluated brensocatib in adult patients with moderate to severe hidradenitis suppurativa (HS), did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms. Brensocatib was well tolerated, with no new safety</description>
</item>
<item>
<title>Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-announces-positive-topline-results-from-phase-3b-encore-study-of-arikaycer-amikacin-liposome-inhalation-suspension-in-patients-with-mac-lung-disease</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-announces-positive-topline-results-from-phase-3b-encore-study-of-arikaycer-amikacin-liposome-inhalation-suspension-in-patients-with-mac-lung-disease</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>—The Study Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints, Demonstrating Statistically Significant and Clinically</description>
</item>
<item>
<title>Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 19 Feb 2026 12:00:00 GMT</pubDate>
<description>Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.</description>
</item>
<item>
<title>Insmed To Present at March 2026 Investor Conferences</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-present-march-2026-investor-120000394</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-present-march-2026-investor-120000394</guid>
<pubDate>Fri, 13 Feb 2026 12:00:00 GMT</pubDate>
<description>Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:</description>
</item>
<item>
<title>Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-host-fourth-quarter-full-120000283</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-host-fourth-quarter-full-120000283</guid>
<pubDate>Thu, 05 Feb 2026 12:00:00 GMT</pubDate>
<description>Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its fourth-quarter and full-year 2025 financial results on Thursday, February 19, 2026.</description>
</item>
<item>
<title>Definium Therapeutics Appoints Roger Adsett to Board of Directors</title>
<link>https://6ix.com/company/insmed-inc/news/definium-therapeutics-appoints-roger-adsett-to-board-of-directors-1</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/definium-therapeutics-appoints-roger-adsett-to-board-of-directors-1</guid>
<pubDate>Thu, 29 Jan 2026 12:00:00 GMT</pubDate>
<description>NEW YORK, January 29, 2026--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately.</description>
</item>
<item>
<title>Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-present-multiple-abstracts-treprostinil-palmitil-inhalation-powder-tpip</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-present-multiple-abstracts-treprostinil-palmitil-inhalation-powder-tpip</guid>
<pubDate>Wed, 28 Jan 2026 05:00:00 GMT</pubDate>
<description>—Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging</description>
</item>
<item>
<title>Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-provides-business-update-44th-annual-jp-morgan-healthcare-conference-2026-01</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-provides-business-update-44th-annual-jp-morgan-healthcare-conference-2026-01</guid>
<pubDate>Fri, 09 Jan 2026 05:00:00 GMT</pubDate>
<description>— BRINSUPRI® (brensocatib) Unaudited Total Revenues of Approximately $144.6 Million for First Full Quarter of Launch; Approximately $172.7 Million for</description>
</item>
<item>
<title>Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-present-44th-annual-jp-morgan-healthcare-conference-2026-01-02</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-present-44th-annual-jp-morgan-healthcare-conference-2026-01-02</guid>
<pubDate>Fri, 02 Jan 2026 05:00:00 GMT</pubDate>
<description>BRIDGEWATER, N.J., Jan. 2, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first-</description>
</item>
<item>
<title>Insmed Provides Clinical and Business Update</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-provides-clinical-and-business-update-2025-12-17</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-provides-clinical-and-business-update-2025-12-17</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>—Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed</description>
</item>
<item>
<title>Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12-04</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12-04</guid>
<pubDate>Thu, 04 Dec 2025 05:00:00 GMT</pubDate>
<description>BRIDGEWATER, N.J., Dec. 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first-</description>
</item>
<item>
<title>European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union</title>
<link>https://6ix.com/company/insmed-inc/news/european-commission-approves-brinsupritm-brensocatib-first-and-only-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/european-commission-approves-brinsupritm-brensocatib-first-and-only-treatment</guid>
<pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
<description>— Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI Is a</description>
</item>
<item>
<title>Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-strengthens-communities-worldwide-during-fourth-annual-global-day-good-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-strengthens-communities-worldwide-during-fourth-annual-global-day-good-2025-11</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>More than 1,200 employees across the U.S., Europe, and Japan unite to support multiple organizations during annual company-wide day of service BRIDGEWATER,</description>
</item>
<item>
<title>Insmed To Present at November and December 2025 Investor Conferences</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-present-november-and-december-2025-investor-conferences-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-present-november-and-december-2025-investor-conferences-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>BRIDGEWATER, N.J., Nov. 5, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver</description>
</item>
<item>
<title>Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-reports-third-quarter-2025-financial-results-and-provides-business-update-2025</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-reports-third-quarter-2025-financial-results-and-provides-business-update-2025</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>—BRINSUPRI ™ (brensocatib) Approved by FDA as First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis; Positive CHMP Opinion Adopted in the European</description>
</item>
<item>
<title>Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-ranks-no-1-sciences-2025-top-biopharma-employers-list-2025-10-23</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-ranks-no-1-sciences-2025-top-biopharma-employers-list-2025-10-23</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>—Insmed Leads Science Top Employers List for Fifth Year in a Row— BRIDGEWATER, N.J., Oct. 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a</description>
</item>
<item>
<title>CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis</title>
<link>https://6ix.com/company/insmed-inc/news/chmp-recommends-eu-approval-brinsupritm-brensocatib-treatment-non-cystic-fibrosis</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/chmp-recommends-eu-approval-brinsupritm-brensocatib-treatment-non-cystic-fibrosis</guid>
<pubDate>Fri, 17 Oct 2025 04:00:00 GMT</pubDate>
<description>— If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class</description>
</item>
<item>
<title>Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-present-multiple-analyses-phase-3-aspen-study-american-college-chest</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-present-multiple-analyses-phase-3-aspen-study-american-college-chest</guid>
<pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
<description>—Data on Structural Lung Changes from a High-Resolution CT Substudy to be Presented as Late-Breaker— —Additional Analyses Will Highlight Efficacy, Symptom</description>
</item>
<item>
<title>Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025</title>
<link>https://6ix.com/company/insmed-inc/news/insmed-host-third-quarter-2025-financial-results-conference-call-thursday-october-30</link>
<guid isPermaLink="true">https://6ix.com/company/insmed-inc/news/insmed-host-third-quarter-2025-financial-results-conference-call-thursday-october-30</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>BRIDGEWATER, N.J., Oct. 15, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver</description>
</item>
</channel>
</rss>